6 men, among which 2 in critical condition, became ill and are currently in intensive care after taking an anti-inflammatory drug as part of a drug trial. The drug TGN1412, a monoclonal antibody developed by TeGenero AG, was developed for the treatment of autoimmune and inflammatory diseases and leukemia. Ganesh Suntharalingam, clinical director of intensive care at Northwick Park Hospital, where the men are hospitalized, said two of them were in critical condition and four were in serious condition but showing signs of improvement. "The drug, which is untested and therefore unused by doctors, has caused an inflammatory response which affects some organs of the body," he added. The trials were conducted by the research organization Parexel International. TeGenero's chief executive Dr. Benedikte Hatz stated referring to these cases: "These events were completely unexpected and do not reflect the results we obtained from initial laboratory studies, which enabled us to progress investigations into human volunteers." One sickened man's girlfriend, Myfanwy Marshall, said he decided to take part in the tests because it paid around £2,000 and the man needed some money. "He saw the ad, he told me it was for a leukemia drug. He'd taken part in trials before and been fine. I didn't want him to do it, but he said he was helping mankind, helping scientific knowledge," she stated. So far, doctors are in dark about the drug. They do not know about it or its effects. It hasn't been tested on humans so they do not know what they are dealing with. They only certain thing is that TGN1412 must be eliminated from the patients' bodies.